Latest News !
 

Biotech Daily Editorial: BNYM & Substantial Shareholder Notices

Dr Boreham's Crucible: Heramed

Ausbiotech: 'Threat To R&D Incentive Worries Sector'

Minister Karen Andrews Talks Biotech

Dr Boreham's Crucible: Oncosil Medical

Federal Election 2019: Policies & Comment

Orthocell Up 377% On 4-Patient Celgro Nerve Regeneration

Actinogen: 'Xanamem Fails Alzheimer's Endpoints'; Falls 71%

Paradigm Raising $78m On PPS Osteoarthritis Pain Trial Results

Federal Budget 2019 - Comment & Analysis

Oncosil Falls 87% On Pancreatic Cancer Radiation Doubts

2018 - The Year In Review

May BDI-40 Up 6.5%, Big Caps Up 4%, ASX200 Up 1%, NBI Down 6%

 Orthocell Up 418%, LBT 106%, Prescient 42%
Actinogen Down 78%, Impedimed 40%

 

June 3, 2019

 

May continued the Biotech Daily Top 40 Index (BDI-40) run, breaking through the record collective $10 billion market capitalization mark last month and $11 billion this month.

 

The BDI-40 (which does not include the Big Caps of Cochlear, CSL and Resmed) climbed a further 6.5 percent in May, following the April 18.1 percent jump, easily out-performing the ASX200 which was up 1.1 percent.

 

The three Big Caps of Cochlear, CSL and Resmed rose a collective 4.3 percent and the Nasdaq Biotechnology Index (NBI) fell a further 6.1 percent.

 

For the year to May 31, 2019 the BDI-40 was up 31.3 percent, the Big Caps were up 10.75 percent, the ASX200 improved 6.4 percent and the NBI fell 7.9 percent.

 

In May, 16 of the BDI-40 stocks were up; 11 by more than 10 percent and six by more than 20 percent; while 18 fell, with eight losing more than 10 percent; and six were unchanged.

 

Clinuvel added the most to the market cap index, up $479 million to $1649 million, while the percentage best, from a much lower base, was Orthocell on the news of four Celgro patients regaining muscle function and sensation, up a sensational and muscly $46 million or 418.2 percent to $57 million in the month.

 

LBT was second best on an FDA approval for its APAS Independence, up 106.25 percent  to $33 million, followed by Prescient (41.7%), Clinuvel (40.9% for the month and 184.3% for the year), Telix (21.1%), Patrys (20.8%), Compumedics (18.4%), Oncosil (17.6%), Polynovo (15.9%), Pro Medicus (14.8%) and Avita (11.8%).

 

Actinogen led the falls on non-significance for Xanamem for Alzheimer’s disease, down $45 million or 77.6 percent to $13 million, followed by Impedimed (40.4%), Osprey (25.4%), Alterity (Prana, 17.1%), Benitec (16.2%), Kazia (13.3%), Nanosonics (12.75%) and Universal Biosensors (12.5%).

 

Resmed was up 11.3 percent to $23,394 million, Cochlear rose 5.0 percent to $11,353 million, with CSL up 2.5 percent to $92,240 million.

 

Outside the Top 40, Alcidion, Elixinol, Medadvisor, Painchek and Resonance were all contenders for promotion.

 

The 16 stocks in Cannabis Corner were up 8.1 percent to a collective market capitalization of $1,744 million, with 11 companies up, four down and two unchanged.

 

On the Nasdaq, Vaxart (Biota) recovered from its all-time low, up 66.7 percent to $15 million, Eyepoint (Psivida) was up 3.9 percent to $240 million, Queensland’s Protagonist lost 0.6 percent to $339 million and Israel’s Redhill (with Australian assets) shed 25.5 percent to $234 million.

 

BDI-40 v S&P ASX200 Jun 30, 2006 to May 31, 2019 

 

3-Year Big Caps (Cochlear, CSL, Resmed) to May 31, 2019

BDI-40 ($m) v S&P ASX200 – Year to May 31, 2019 (current, raw data)